Taiwan Tfda Medical Device Registration Consultant

Scope and evidence must be confirmed before any paid tests or filings.

Start with a regulatory decision, not a filing quote

A Taiwan TFDA medical device registration consultant should first produce a defendable route decision—not promise an approval date. Taiwan’s Medical Devices Act covers qualifying instruments, software and in-vitro reagents by intended action; a foreign CE mark or FDA authorization does not by itself decide the Taiwan classification or permit import.

The strategic output is a scoped assessment of the product claims, applicable Taiwanese classification item, registration versus listing, eligible applicant, QMS/GDP dependencies and the evidence that must be generated or adapted. This page is about deciding the route before paying for tests or instructing a filing agent.

Classify the actual Taiwan claim and product

Freeze the intended use, patient population, user, clinical claim, mechanism and whether software influences diagnosis or therapy; marketing claims must match the technical description.
Match the device to the current Taiwan classification annex and record both item code and Class I, II or III. If several items apply, assess the highest-risk rule; dedicated accessories and combined products need their own analysis.
Do not guess Class I when the device is absent from the annex: Article 6 can point to Class III unless a qualifying locally licensed/listed predicate or a competent-authority classification response supports a different risk level.
Map each model, accessory, kit component, sterilization state and brand name. TFDA allows some model variants under one license only when classification code, product name, manufacturer and intended use align.
If the product tests human specimens, flag the IVD pathway and the need for IVD-specific evidence; do not import a non-IVD checklist uncritically.
Check effective dates, not just annex titles: the amended classification item I.4040 (medical apparel) took effect on 22 August 2026. Revalidate any earlier item mapping against the currently effective annex and any relevant item-specific notice.

Choose the authorization route only after classification

Provisional finding	Decision and evidence needed	Do not assume
Outside device definition	Document intended action and obtain a defensible scope conclusion; seek TFDA clarification where doubtful.	An EU/US designation settles the Taiwan question.
Announced product item eligible for listing	Verify the specific TFDA announcement; prepare listing particulars and supporting files under Article 20.	Every Class I item is automatically a listing.
Licensed product, including non-listed Class I and generally Class II/III	Identify the Taiwan item code, product grouping, applicant and applicable appendices before assembling a license application.	Class alone determines the paperwork or every test is compulsory.
Novel, borderline or conflicting classification	Prepare a reasoned written classification inquiry supported by IFU, operating principle and foreign reference classifications when available.	An unverified predicate or a consultant’s opinion is binding on TFDA.

Separate from routine commercial authorization, Article 35 permits TFDA special approval only in specified circumstances, including qualifying investigations, emergencies, samples, personal use and repair-only imports. Establish the import purpose and obtain the applicable special approval where needed; do not market a special-approval consignment as an ordinarily licensed or listed product.

Evidence reuse: what travels and what needs local work

Evidence bundle	Reuse assessment	Decision before spending
Foreign clearance, free-sale certificate and manufacturer authorization	Useful provenance and administrative support; determine current document form and relevance under the applicable TFDA appendix.	Check validity, manufacturer identity, intended use and any authentication requirements; not automatic recognition.
ISO 13485, site records and quality documents	Can support QMS evaluation, but ISO certification does not replace an applicable Taiwan manufacturing-license/QMS assessment.	Identify the actual overseas manufacturer, sites, scope and any legally available exemption.
Bench, electrical, biological, software or cybersecurity reports	Reuse only where the tested version, claims, methods and relevant TFDA requirements align.	Create a test-to-claim gap matrix; confirm recognized standard editions before ordering retests.
Clinical/performance evidence and Taiwan predicates	Clinical data and comparable domestic licensed/listed devices may affect the evaluation; equivalence must be substantiated, not asserted.	Check clinical indications, technical differences and whether Taiwan-specific clinical evidence is needed.
Labels, instructions and model matrix	Source artwork helps translation, but Taiwan Article 32 generally requires Chinese labels and instructions before sale, subject to announced/approved exceptions.	Reconcile product names, license/listing holder, model scope and final claims before translations or packaging print.

Decide who can act and who controls the authorization

A consultant can analyse, coordinate and draft; these are not automatically the legal powers of a medical device firm. Article 13 generally requires the relevant medical device business permit, and Article 25 limits importing to the license/listing holder or an authorized person. For imported QMS inspection, the QMS-inspection regulations identify the importer as the applicant.

Before signing an agency or distribution agreement, map the actual permit holder, applicant, manufacturer, importer, authorization owner, record custodian, complaint contact and exit/transfer rights. Some designated device dealers also require GDP compliance and a distribution license under Article 24; do not apply that extra license to every dealer without checking the announced scope.

A contractual exit or transfer clause does not itself transfer a Taiwan medical-device license or listing. In particular, Article 21 of the listing regulations permits changes to the listed firm's name only without a transfer of rights. Before replacing an applicant or importer, establish the actual TFDA change or new-authorization route and continuity responsibilities.

A TFDA procedural pilot effective 1 October 2026 changes evidence custody for Class I–III registration, license amendments and extensions submitted through its electronic filing system: applicants upload colour PDF scans of required originals and retain those originals for inspection, rather than sending them routinely. Do not treat this as a universal waiver of originals or of any separate document-authentication rule; check the filing channel and case type.

Post-approval exception: where an electronic license-amendment or extension application is approved, TFDA still requires a copy of the approval letter and the original medical-device license to be mailed within one month of receipt of the approval letter for annotation. Keep this step in the license-holder's handoff plan; the original-retention pilot does not eliminate it.

Five gates before testing or submitting

Gate 1 — claim lock: approve the intended-use text, physical/software versions and Taiwan product family; stop if a drug/device boundary remains unresolved.
Gate 2 — classification: save the annex item, rationale and any regulatory inquiry outcome; stop if grouping or predicate evidence is speculative.
Gate 3 — responsibility: verify the Taiwan business permit and importer/manufacturer authorizations, plus QMS and any product-specific GDP prerequisites.
Gate 4 — evidence delta: rank missing materials as essential to route, essential to safety/performance, or localization only; buy tests only against identified gaps.
Gate 5 — filing handoff: issue a signed decision memo, open questions, filing owner, version-controlled dossier index and a plan for TFDA requests and post-market changes.

Failure modes and lifecycle obligations

CE/FDA approval is evidence, not automatic Taiwan clearance. A product’s US or EU class is not a substitute for applying Taiwan’s annex and special rules.
No universal promise of clinical-trial exemption, expedited route, fixed approval time or one standard test package is reliable without device-specific facts. Article 37 contains a separate clinical-trial authorization framework with stated exceptions.
Article 32 addresses Chinese labelling; Articles 26–28 and 48–49 address controlled changes, license expiry/listing annual declaration and incident/corrective duties. For listed devices, the detailed rules set an October annual declaration after one year.
The TFDA pages for QMS and GDP currently show a page update of 3 June 2026, but their displayed legal amendment dates are earlier. Recheck live legal text and product-specific announcements; a website update alone is not a legal amendment.
Also from 1 October 2026, for approved Class II/III registration and change cases TFDA replaces paper-approved label, instructions and packaging copies with electronic approved versions in its license system, including cases filed on paper. That is a procedural change, not a relaxation of Chinese-labelling or approval requirements.

What a useful consultant assessment delivers

Classification memo: medical-device scope, Taiwan annex code/class, competing interpretations and confidence level.
Route matrix: listing versus license, grouped product names/models, applicable official appendices, unanswered TFDA questions.
Evidence delta register: each dossier item mapped to claim, version, source, owner, reuse status and acceptance risk.
Responsibility and launch sequence: verified applicant/importer/QMS/GDP roles, gates, follow-up triggers and cost drivers—not guaranteed review dates.

Where filing execution begins

Once the route is signed off, the operational document preparation and submission belongs to the Taiwan medical device registration service.

For specimen-based diagnostics, use the dedicated Taiwan IVD filing service.

For a broader country/regime screen, use the Taiwan product market-access overview.

Questions manufacturers ask before appointing a consultant

Does Class I always mean simple online listing?

No. Listing applies only to product items announced for listing under Article 25. Other Class I products can require license registration; verify the exact item and its current announcement first.

Our device has CE marking and an FDA clearance. Can we skip Taiwan classification or testing?

No automatic waiver follows from either approval. Use foreign documents as evidence, then match the Taiwan annex item, intended use, technical version and each required evidence category.

What if no Taiwan classification item fits our novel software?

Record the claims and working principle, search for a qualifying Taiwan predicate, and consider the Article 5 official classification inquiry. Article 6 contains a Class III default in the absence of a fitting item, subject to its predicate/inquiry provision.

Can our overseas manufacturer submit without a Taiwan importer?

Do not assume so. The Medical Devices Act requires the appropriate medical device business status for regulated operations, and QMS-inspection rules specifically identify the importer for applications involving imported products. Verify the proposed legal applicant and authorizations.

Should we commission local tests before appointing the consultant?

Usually the safer order is classification → route → evidence gap review → targeted testing. Testing should be justified against the actual model, intended use and applicable TFDA requirements, not bought from a generic list.